Likewise, the currently available literature is inconclusive regarding levels of total protein in saliva at stress. Several studies report stress-induced increases of total protein concentration in saliva. Conversely, no differences in total salivary protein were observed between stressed and nonstressed subjects. In the present study, no significant differences of salivary flow rate or total protein concentration were found for both conditions. Also, no associations were found between the basic salivary measurements and the markers of prooxidant-antioxidant balance. Therefore, we can assume that the observed changes of prooxidant-antioxidant markers in response to stress were not due to unchanged levels of catalase, oxidatively modified proteins, malonic dialdehyde or sialic acids in an altered volume of saliva or a different amount of protein. The study has a number of limitations. Extrapolation of our findings may be limited to young healthy people. Additionally, we were only able to assess prooxidant-antioxidant changes at the onset of stress, while different patterns of response may emerge over longer time periods. Glioblastoma is the most common primary malignant brain tumor with two-year survival rates of less than 30%. Despite aggressive surgery, radiation therapy, and chemotherapy, median survival remains in the range of 15 months. The hallmarks of glioblastoma include rapid progression and high degree of vascularity. Several therapeutic approaches have been tested to treat glioblastoma tumors, but none of these can extend survival for more than a few months. In recent years, significant research efforts have focused on the use of anti-angiogenic therapies for the treatment of glioblastoma. These drugs have the potential to normalize abnormal tumor vasculature structurally and functionally, reduce the risk of hemorrhage, enhance the penetration of concurrently administered chemotherapy and improve the efficacy of cytotoxic drugs and radiation by alleviating hypoxia. Bevacizumab, a monoclonal antibody that inactivates vascular endothelial growth factor, was lately approved by the US Food and Drug Administration for treatment of recurrent glioblastoma. It reduces MRI enhancement, and provides benefit by controlling peritumoral edema and improving clinical performance. Its clinical use is becoming more widespread, even though its effect on overall survival and its anti-glioma effect remain questionable. Besides angiogenesis, phenomena such as vascular co-option and vascular mimicry were also evident in glioblastoma, especially following antiangiogenic therapies. Magnetic resonance images is the method-of-choice for noninvasive whole brain assessment of brain tumors, having an essential role in classification, grading, follow-up and therapeutic management, due to its soft tissue resolution, safety and diversity. MRI can LEE011 provide structural, biochemical and functional information regarding the tumor and its surrounding parenchyma.